Log in

Eton Pharmaceuticals Stock Forecast, Price & News

+0.10 (+1.22 %)
(As of 09/25/2020 12:00 AM ET)
Today's Range
Now: $8.28
50-Day Range
MA: $7.46
52-Week Range
Now: $8.28
Volume988,298 shs
Average Volume222,482 shs
Market Capitalization$173.52 million
P/E RatioN/A
Dividend YieldN/A
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis. It also develops DS-300, an injectable nutrition product candidate for neonates; DS-200, an injectable nutrition product for use as a supplement to intravenous solutions; and DS-100, an injectable nerve block for the relief of intractable pain. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ETON



Sales & Book Value

Annual Sales$460,000.00
Book Value$0.59 per share


Net Income$-18,320,000.00


Market Cap$173.52 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
+0.10 (+1.22 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ETON News and Ratings via Email

Sign-up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Eton Pharmaceuticals (NASDAQ:ETON) Frequently Asked Questions

How has Eton Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Eton Pharmaceuticals' stock was trading at $4.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ETON shares have increased by 97.1% and is now trading at $8.28.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Eton Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Eton Pharmaceuticals

When is Eton Pharmaceuticals' next earnings date?

Eton Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Eton Pharmaceuticals

How were Eton Pharmaceuticals' earnings last quarter?

Eton Pharmaceuticals Inc (NASDAQ:ETON) issued its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.03. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.33 million.
View Eton Pharmaceuticals' earnings history

What price target have analysts set for ETON?

2 brokers have issued 1-year target prices for Eton Pharmaceuticals' shares. Their forecasts range from $10.00 to $18.00. On average, they expect Eton Pharmaceuticals' share price to reach $14.00 in the next twelve months. This suggests a possible upside of 69.1% from the stock's current price.
View analysts' price targets for Eton Pharmaceuticals

Are investors shorting Eton Pharmaceuticals?

Eton Pharmaceuticals saw a increase in short interest in September. As of September 15th, there was short interest totaling 792,700 shares, an increase of 18.3% from the August 31st total of 669,800 shares. Based on an average trading volume of 474,300 shares, the days-to-cover ratio is presently 1.7 days. Approximately 5.6% of the company's shares are sold short.
View Eton Pharmaceuticals' Short Interest

Who are some of Eton Pharmaceuticals' key competitors?

What other stocks do shareholders of Eton Pharmaceuticals own?

Who are Eton Pharmaceuticals' key executives?

Eton Pharmaceuticals' management team includes the following people:
  • Mr. Sean E. Brynjelsen, Pres, CEO & Director (Age 47)
  • Mr. W. Wilson Troutman CPA, CFO, Treasurer & Sec. (Age 64)

When did Eton Pharmaceuticals IPO?

(ETON) raised $22 million in an IPO on Wednesday, November 14th 2018. The company issued 3,600,000 shares at a price of $6.00 per share. National Securities Corporation served as the underwriter for the IPO.

What is Eton Pharmaceuticals' stock symbol?

Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON."

Who are Eton Pharmaceuticals' major shareholders?

Eton Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include AWM Investment Company Inc. (3.83%), Westside Investment Management Inc. (0.39%), Charles Schwab Investment Management Inc. (0.23%), Nuveen Asset Management LLC (0.18%), Bank of America Corp DE (0.16%) and Bank of New York Mellon Corp (0.16%). Company insiders that own Eton Pharmaceuticals stock include Charles J Casamento, Sean Brynjelsen and William Wilson Troutman.
View institutional ownership trends for Eton Pharmaceuticals

Which institutional investors are selling Eton Pharmaceuticals stock?

ETON stock was sold by a variety of institutional investors in the last quarter, including AWM Investment Company Inc., and UBS Group AG.
View insider buying and selling activity for Eton Pharmaceuticals

Which institutional investors are buying Eton Pharmaceuticals stock?

ETON stock was acquired by a variety of institutional investors in the last quarter, including Charles Schwab Investment Management Inc., Nuveen Asset Management LLC, Bank of America Corp DE, Westside Investment Management Inc., Bank of New York Mellon Corp, Jane Street Group LLC, New York State Common Retirement Fund, and American International Group Inc.. Company insiders that have bought Eton Pharmaceuticals stock in the last two years include Charles J Casamento, Sean Brynjelsen, and William Wilson Troutman.
View insider buying and selling activity for Eton Pharmaceuticals

How do I buy shares of Eton Pharmaceuticals?

Shares of ETON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eton Pharmaceuticals' stock price today?

One share of ETON stock can currently be purchased for approximately $8.28.

How big of a company is Eton Pharmaceuticals?

Eton Pharmaceuticals has a market capitalization of $173.52 million and generates $460,000.00 in revenue each year. The company earns $-18,320,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Eton Pharmaceuticals employs 15 workers across the globe.

What is Eton Pharmaceuticals' official website?

The official website for Eton Pharmaceuticals is www.etonpharma.com.

How can I contact Eton Pharmaceuticals?

Eton Pharmaceuticals' mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The company can be reached via phone at 847-787-7361 or via email at [email protected]

This page was last updated on 9/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.